{{ AI techniques are making inroads into the field of drug discovery. As a result, a growing number of drugs and vaccines have been discovered using AI. However, questions remain about the success of these molecules in clinical trials. To address these questions, we conducted a first analysis of the clinical pipelines of AI-native Biotech companies. In Phase I we find AI-discovered molecules have an 80-90% success rate, substantially higher than historic industry averages. This suggests, we argue, that AI is highly capable of designing or identifying molecules with drug-like properties. In Phase II the success rate is ∼40%, albeit on a limited sample size, comparable to historic industry averages. Our findings highlight early signs of the clinical potential of AI-discovered molecules. }}
“historic industry averages” is a poor comparison. Newer equipment for testing multiple molecules is a game changer. History did not have the equipment. The study uses the drug candidates that come out of a huge sampling of thousands of molecules.
Snippet from Abstract on link
This suggests, we argue, that AI is highly capable of designing or identifying molecules with drug-like properties. In Phase II the success rate is ∼40%, albeit on a limited sample size, comparable to historic industry averages. Our findings highlight early signs of the clinical potential of AI-discovered molecules.
My comment is only Phase II because it is new to the field but on pretty much the same trajectory as usual with the possible drug candidates. Only about 6% of drugs make it through Phase IV. In the open market more fail within the first five years to be safe or have efficacy.
The Pharma corporations may not want to use AI. The patent office might reject work not done by human beings.
At least when it comes to copyright art created by AI there is no copyrighted.
When machines do the work humans can not claim to have a copyright. The art is in the public domain.
adding just looked it up
The USPTO has taken a similar approach to other national courts and patent offices on prohibiting the listing of AI as an inventor on a patent or patent application. The new USPTO guidance is aligned with similar approaches from the United Kingdom Intellectual Property Office and the European Patent Office.Feb 13, 2024
The AI is not the inventor or author in any significant sense, and it is important to NOT confuse this sort of AI with those doing simulated creative arts such as images, music, or writings.
The AIs generating drug candidates are simply very high speed sorter/calculators of how to assemble bio-active molecules, mostly proteins, that fit a certain profile.